These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17275943)

  • 1. Mechanisms controlling protein release from lipidic implants: effects of PEG addition.
    Herrmann S; Winter G; Mohl S; Siepmann F; Siepmann J
    J Control Release; 2007 Apr; 118(2):161-8. PubMed ID: 17275943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insight into the role of polyethylene glycol acting as protein release modifier in lipidic implants.
    Herrmann S; Mohl S; Siepmann F; Siepmann J; Winter G
    Pharm Res; 2007 Aug; 24(8):1527-37. PubMed ID: 17380261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel mathematical model quantifying drug release from lipid implants.
    Siepmann F; Herrmann S; Winter G; Siepmann J
    J Control Release; 2008 Jun; 128(3):233-40. PubMed ID: 18442866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug release from lipid-based implants: elucidation of the underlying mass transport mechanisms.
    Guse C; Koennings S; Kreye F; Siepmann F; Goepferich A; Siepmann J
    Int J Pharm; 2006 May; 314(2):137-44. PubMed ID: 16503388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous release of Rh-interferon (alpha-2a from triglyceride implants: storage stability of the dosage forms.
    Mohl S; Winter G
    Pharm Dev Technol; 2006 Feb; 11(1):103-10. PubMed ID: 16544914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid extrudates as novel sustained release systems for pharmaceutical proteins.
    Schulze S; Winter G
    J Control Release; 2009 Mar; 134(3):177-85. PubMed ID: 19121347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug release mechanisms of compressed lipid implants.
    Kreye F; Siepmann F; Siepmann J
    Int J Pharm; 2011 Feb; 404(1-2):27-35. PubMed ID: 21055453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants.
    Desai KG; Mallery SR; Schwendeman SP
    Eur J Pharm Biopharm; 2008 Sep; 70(1):187-98. PubMed ID: 18472254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Confocal microscopy for the elucidation of mass transport mechanisms involved in protein release from lipid-based matrices.
    Koennings S; Tessmar J; Blunk T; Göpferich A
    Pharm Res; 2007 Jul; 24(7):1325-35. PubMed ID: 17457662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous release of rh-interferon alpha-2a from triglyceride matrices.
    Mohl S; Winter G
    J Control Release; 2004 May; 97(1):67-78. PubMed ID: 15147805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug release from extruded solid lipid matrices: theoretical predictions and independent experiments.
    Güres S; Siepmann F; Siepmann J; Kleinebudde P
    Eur J Pharm Biopharm; 2012 Jan; 80(1):122-9. PubMed ID: 22008146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NIR spectroscopy-a non-destructive analytical tool for protein quantification within lipid implants.
    Schönbrodt T; Mohl S; Winter G; Reich G
    J Control Release; 2006 Aug; 114(2):261-7. PubMed ID: 16872710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled release implants based on cast lipid blends.
    Kreye F; Siepmann F; Zimmer A; Willart JF; Descamps M; Siepmann J
    Eur J Pharm Sci; 2011 May; 43(1-2):78-83. PubMed ID: 21463679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
    Badr-Eldin SM; Elkheshen SA; Ghorab MM
    Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous controlled vitamin release from multiparticulates: theory and experiment.
    Seidenberger T; Siepmann J; Bley H; Maeder K; Siepmann F
    Int J Pharm; 2011 Jun; 412(1-2):68-76. PubMed ID: 21515349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling drug release from hot-melt extruded mini-matrices with constant and non-constant diffusivities.
    Verhoeven E; Siepmann F; De Beer TR; Van Loo D; Van den Mooter G; Remon JP; Siepmann J; Vervaet C
    Eur J Pharm Biopharm; 2009 Oct; 73(2):292-301. PubMed ID: 19549569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage?
    Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Xiu X; Li Y; Wei N
    J Pharm Sci; 2011 Jul; 100(7):2835-48. PubMed ID: 21305545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclodextrin controlled release of poorly water-soluble drugs from hydrogels.
    Woldum HS; Larsen KL; Madsen F
    Drug Deliv; 2008 Jan; 15(1):69-80. PubMed ID: 18197526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The release behavior of doxorubicin hydrochloride from medicated fibers prepared by emulsion-electrospinning.
    Xu X; Chen X; Ma P; Wang X; Jing X
    Eur J Pharm Biopharm; 2008 Sep; 70(1):165-70. PubMed ID: 18472256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergetic skin targeting effect of hydroxypropyl-β-cyclodextrin combined with microemulsion for ketoconazole.
    Che J; Wu Z; Shao W; Guo P; Lin Y; Pan W; Zeng W; Zhang G; Wu C; Xu Y
    Eur J Pharm Biopharm; 2015 Jun; 93():136-48. PubMed ID: 25845772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.